View Systems designs, develops, and markets computer software and hardware associated with surveillance systems capabilities. The View Systems product line-up includes ViewScan Concealed Weapons Detection System which is best described as a walk-through concealed weapons detector leveraging data sensing technology to determine the location, size, and number of concealed weapons on a person or within their belongings. Also, VSYM sells 3D facial recognition and identify management solutions and ViewMaxx Digital Video System, a high-resolution, digital video recording, and monitoring system.

In addition, the company offers training and service programs involving on-site consulting with customer engineers, installation and technical support, training and train the trainer programs supported by extended service agreements. View Systems targets government and law enforcement agencies, private businesses, commercial security professionals and the residential market.

Among several other security systems offered by the company is its School Security Product offering – ViewScan. The system serves as a personnel screening device than can detect guns, knives, and other potential threat objects. The product does not require removal of jewelry or shoes during screening. Easy to operate, ViewScan is capable of scanning over four times faster than conventional airport screening systems. Each unit comes complete with a laptop loaded with View’s proprietary software. As a student or visitor passes through the portal, a photograph is taken by the integrated camera system and stored. Weapons and other threat objects are visually located on the computer screen which in turn sounds an alert. The graphical interface displays the detected object’s location on the image of the scanned person and facilitates standard and efficient secondary screening.

Customers benefit from the ability to customize Viewscan to align with their unique environment, and the unit can be integrated with card readers and biometrics. Each Viewscan weighs just shy of 65 pounds and all have portability features that make them easy to relocate to any venue where personnel screening is needed. Producing no harmful emissions, the system is 100% safe for pregnant women and people with pacemakers.

The company continues to conduct research to ensure its technologies evolve with the changing security environment. Leading this charge is a senior management team comprised of successful businessmen with decades of business and professional experience in the security industry. View Systems, Inc. was founded in 1989 and is headquartered in Baltimore, Maryland.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board

Through the commercialization of its proprietary cannabis cultivation technology, GrowBLOX Sciences, Inc. (OTCQB: GBLX) is building a formidable presence in the burgeoning medicinal cannabis industry. In order to capitalize on this position, the company plans to utilize a specialized three phase retail distribution solution that will allow for comprehensive coverage of the country’s legalized medicinal cannabis markets.

Phase one of GrowBLOX’s projected retail channel solutions is The Apothecary. This unique retail environment combines a simple, clean and clinical design with cutting-edge biometrics and patient verification to ensure a pleasant and safe customer experience. When visiting The Apothecary, patients will have access to highly trained and certified patient-care professionals, who will help determine medical needs and identify therapeutic solutions. Since doctors have limited training in the benefits of cannabinoid therapy products, these professionals are essential to the company’s patient education efforts. For an inside view of The Apothecary, visit https://vimeo.com/129493221.

In order to expand its retail distribution network and bypassing the costs of traditional brick and mortar locations, GrowBLOX Sciences will also offer a collection of Micro-Apothecary self-service vending kiosks, which will serve as phase two of the company’s retail channel solutions. These machines will provide validated patients with a quick and easy way to obtain the company’s products. Since the Micro-Apothecary can be installed in any existing retail location or traditional pharmacy permitted to sell medical cannabis products or distribute clinical trial medication doses. This prudent approach offers GBLX a cost-effective method of exponentially expanding its distribution network in the years to come.

The final phase of the company’s projected retail network is its innovative mobile app. Set to be released in the second half of 2015, this powerful tool will allow patients to generate profiles, track symptoms, browse local inventory options and order products for pickup or delivery through the use of a mobile device. This mobile app will be essential for tracking valuable patient data and streamline distribution efforts beyond the bounds of its physical locations in order to maximize potential growth moving forward.

With a full network of projected retail channel solutions in place, GBLX is in a solid position to promote strong returns in the future. In the coming months, look for the company to continue building upon its recent commercial progress in an effort to maximize market share within the expanding medicinal cannabis industry.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

Pure Hospitality Solutions (OTC:PNOW) is developing efficient tools to enable travelers to book lodging accommodations in affordable high end luxury units at relatively low cost. To execute this mission, the company primarily focuses on the development and acquisition of condominium apartments in hot-spot tourist destinations like Costa Rica. Pure’s overarching mission is to compete alongside travel industry behemoths like Expedia, Inc. (NASDAQ:EXPE), Orbitz Worldwide, Inc. (NYSE:OWW) and Priceline Group, Inc. (PCLN).

In most cases, Pure uses its Friendly Reservations Online (FROL) booking engine to ensure higher occupancy rates in its affiliate condos and that of the individual owners. FROL is currently undergoing a pre-launch overhaul, in which the tool will be branded as an online travel agency (OTA) called Oveedia, which will focus on the Central American-Caribbean region.

Oveedia will be accessible on al devices, and will ultimately incorporate new mobile apps, offer travelers the newest electronic payment options, provide hotel operators and condominium owners with back-end technology services, and operate as a standalone online hospitality search and reservation booking system.

Bigger industry players like Expedia and Orbitz generally charge about 25% of the total reservation amount, according to Pure. These OTAs are essentially third-party travel sites offering virtual billboards to hotels and condominiums looking to market their properties to online travel shoppers. Because these OTAs have amassed high-volume traffic, they are in a position to command higher commission rates.

Pure’s plan is to leverage this OTA billboard model and maintain a competitive edge by offering its hospitality reservation services, utilizing its booking engine, at 8% of the reservation amount. While charging lower commission rates, the company will drive revenues through four key strategies:

1. Initial membership fees charged to each new hotel and condominium properties joining the “by PURE” lodging brand;
2. Monthly royalties from “by PURE” brand locations of no more than 8% of the total Internet reservation sales revenue;
3. Revenue generated from corporate-owned properties;
4. E-marketing revenue.

The company has already signed up a number of properties during past product beta test, and said it believes that through the post-merger/acquisition of various projects located in Costa Rica, it can attract, secure and successfully provide services to approximately 300 participating hotel and condominium owners within the next 12 months.

Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider. The company also intends to establish an international footprint with its online booking engine technology and marketing offerings, making that segment of its business a prime acquisition target for major OTAs.

For more information visit www.purenow.solutions

Let us hear your thoughts: Oriens Travel and Hotel Management Corp. Message Board

Supertel Hospitality is a self-administered real estate investment trust that specializes in the ownership of select-service hotels. The company currently owns 49 hotels in 19 states that are operated by various third-party management companies – including Hilton Hotels and Resorts® (HLT), Choice Hotels® (CHH) and Wyndham® Hotels (WYN) – through franchise agreements.

In recent months, Supertel has initiated a new investment strategy involving upper midscale and upscale hotels in order to maximize shareholder returns in the future. In the first quarter of 2015, the company announced the sale of four hotels around the country for a cumulative sum of $7.5 million. In the second quarter, the company sold three additional properties for $9.3 million, and seven other hotels were also listed for sale as of March 31, 2015. With this influx of capital, Supertel has taken steps toward improving its balance sheet by repaying underlying loans. Following associated debt repayments, these sales are expected to generate approximately $14.5 million in net proceeds, which should enable the company to more effectively adhere to its updated investment strategy.

“The company is actively seeking acquisitions as we expand the efforts to recycle capital into newer hotels with higher margins in sectors and markets with characteristics having the potential to create higher shareholder value,” Bill Blackham, chief executive officer of Supertel, stated in a news release. “As this effort is underway, the underlying hotel portfolio appears to be on track to deliver an increased contribution and that should help to accelerate growing the company during this time of transition.”

Despite its transitional efforts, Supertel has realized noteworthy financial growth from its portfolio of properties in recent months. The company’s first quarter revenue from continuing operations was $12.3 million, which was a 9.3 percent year-over-year increase. Likewise, Supertel’s revenue per available room (RevPAR) improved by 9.9 percent to $35.19 for the period, outperforming the growth of the national hotel industry by nearly two percent.

As the global economy continues to recover moving forward, the hotel industry is expected to experience strong growth. According to a report by Statista, revenue generated by the global hotel industry is expected to climb to $550 billion in 2016, representing a 20 percent improvement over the results of 2011. For Supertel, this industry growth should provide a strong platform to post improved financial results. For prospective investors, the company’s recent efforts to increase shareholder value could foreshadow an opportunity to realize strong returns in the years to come.

For more information, visit www.supertelinc.com

Solaris Power Cells, Inc. (OTCQB: SPCL) is a diversified green energy storage manufacturer offering residential and commercial users turnkey, renewable energy solutions. The company’s proprietary Solaris Power Cell™ utilizes a printed circuit board assembly to provide lead-free, solid-state energy storage that’s both fully renewable and environmentally-friendly.

Although batteries are a common solution for the storage of renewable energy, these systems present engineers with a host of limitations – including short life cycles, high maintenance costs and negative environmental impact. The company’s power cell addresses these shortcomings through its innovative PESA™ (Passive Electron Storage Array). This system utilizes solar panels to charge the array, and, when renewable energy is no longer available, the PESA distributes its stored energy where it’s needed.

The potential market for Solaris’s groundbreaking energy storage system is vast, and it is expected to continue growing in the years to come. According to a report by research firm IHS, the global energy storage market is expected to reach six gigawatts in 2017, which would be an increase of more than 1,750 percent over 2013. Among this growth, the United States is expected to be the largest market for grid-connected energy storage installations.

Solaris also markets its PESA technology in an innovative e-cigarette application. Like all of the company’s products, the F-Series Vapor Mod operates battery-free, allowing for dramatically improved charging speeds and unparalleled lifecycle duration. In June, Solaris announced the release of its unique tobacco-alternative in four custom colors to capitalize on the sales potential presented by the rapidly expanding vaping market. According to The Smoke-Free Alternatives Trade Association, the e-cigarette industry is expected to exceed $10 billion by 2017.

Solaris is in a strong strategic position to make an impact in a variety of potentially lucrative market sectors. For prospective shareholders, Solaris’s innovative approach to the commercialization of its proprietary energy storage technology makes the company an intriguing investment opportunity moving forward.

For more information, visit www.solarispowercells.com

It’s been a busy week for technology innovator Net Element as the company issued a shareholder update, inclusive of the company’s recent financing of at least $10.5 million to sustain further expansion initiatives, as well news that its pending acquisition target has signed a contract to process transactions for several international dating networks.

Net Element leverages its core technology innovations and operational business partners to provide mobile payments and value-added transactional services in emerging countries and in the United States. To this accord, the company is continuously seeking out growth opportunities.

In its recent news release, Net Element defined its primary goal for the second half of 2015 as integrating PayOnline’s value-added technologies with Net Element’s current U.S. offerings to solidify its foothold as a premier payments-as-a-service company with a centralized, omni-channel global platform.

Upon closing of the acquisition, Net Element will be able to sell its mobile payment services to PayOnline’s more than 10 million active consumers and thousands of merchants in the Russian Federation, Europe and Asia.

“The acquisition of PayOnline will be transformative for the Company not only as a profitable acquisition but for the cutting edge payments tools it provides such as its recently announced availability of an online transactional platform for iOS apps (iPhone and iPad),” Net Element said in the news release.

PayOnline’s recent three-year contract centers on a minimum processing commitment of $300 million in transactions for social networks AnastasiaDate, AmoLatina and AsianDate, among others. Net Element currently manages, operates and is in the process of integrating the PayOnline group of companies pending closing of Net Element’s acquisition of the company.

The acquisition will add to Net Element’s current portfolio of subsidiaries, which include TOT Group, Inc., a global mobile payments and transaction processing provider whose companies include Unified Payments, Aptito and TOT Money, and emphasizes Net Element’s ability to facilitate cross-border transactions through a single interface.

“This contract win demonstrates our ability to quickly derive value from strategic acquisitions and partnerships,” Net Element CEO Oleg Firer stated in the news release. “As we emerge from a period of financial and business restructuring, we plan to see more such value driving developments as we progress into our growth phase.”

The financial restructuring mentioned by Firer, along with other achievements and the pending acquisition of PayOnline, triggered a reiterated 12-month price target of $5.17 per share by SeeThruEquity.

“Net Element has achieved several important developments since our last update in March 2015. Most importantly, Net Element made substantial progress shedding cumbersome debt on its balance sheet and announced a new $24.5mn capital raise. While improving its financial position, the company also reported double-digit annual growth in both 1Q15 and fiscal 2014 results and announced several growth initiatives for 2015 and beyond. The company also announced that it had executed definitive documentation for the acquisition of PayOnline, a leader in online transaction processing services and payment technology with over 10mn active consumers and thousands of merchants in the Russian Federation, Europe and Asia. We are reiterating our 12 month price target on NETE of $5.17 per share,” stated SeeThruEquity CEO Ajay Tandon.

Net Element is quick on its feet in taking advantage of opportunities that add momentum to grow revenues, by attracting more merchants to its payments platform, contributing to its overarching mission to become a competitive leader in mobile payments and transactional services in target countries and the United States.

For more information visit www.netelementinc.com

Bollente Companies, Inc. (OTCQB: BOLC), through its trutankless® brand, is a manufacturer and distributor of innovative tankless water heaters in the United States. The company strives to create electric tankless water heaters that far surpass traditional tank water heaters in terms of energy efficiency, output, dependability and environmental sustainability while effectively overcoming the drawbacks of lesser tankless units.

In April, Bollente announced the release of a new line of water heaters geared toward budget-driven customers. These products, known as the Vero™ line, boast the same unrivaled water heating performance, durability and space savings of the trutankless flagship line at a fraction of the cost. Following the enactment of updates to the National Appliance Energy Conservation Act earlier this year, Bollente expects this new product line to provide an opportunity for sustainable market growth in the future.

“The new Department of Energy guidelines for water heaters are going to impact the majority of homes that currently use traditional tank water heaters,” Michael Stebbins, president of trutankless, stated in a news release. “Tanks will become larger and costlier to install, and homes requiring tank heaters that hold 55 or more gallons will have to upgrade to a heat pump for twice the cost, or go tankless. We are pleased to offer whole-home electric tankless solutions that already exceed the new energy factor guidelines.”

The company’s product offerings also include truCirc, a state-of-the-art water circulation pump designed to work seamlessly with its efficient water heaters. truCirc allows users to accurately track water usage throughout their homes and predict when hot water will be needed. By learning usage patterns, the device limits energy usage by keeping water hot only when it is likely to be needed. The product’s intuitive interface also allows homeowners to quickly and easily change delivery modes and zones to minimize wasted water.

“As a standalone product, truCirc provides tremendous energy and water savings for a household,” continued Stebbins. “When used in conjunction with a 99 percent energy-efficient trutankless unit, the end result is a complete water heating system with unrivaled efficiency, durability and long-term value to the homeowner.”

As the home construction industry continues to shift toward more environmentally-friendly solutions, Bollente is in a strong strategic position to record improved financial results. According to a report by McGraw Hill Construction, the overall green single-family housing market is expected to account for more than $80 billion in revenue by 2016, representing a 100 percent increase over the results of 2013. This continued market growth could provide Bollente with an opportunity to post strong results in the future.

Bollente’s proven product line provides the company with a platform to realize continued growth in the months to come. For prospective investors, this growth could translate into sustainable returns moving forward.

For more information, visit www.bollentecompanies.com

BIO-key International, Inc. (OTCQB: BKYI) is a leading provider of advanced fingerprint biometric identification solutions to commercial and government enterprises, integrators and application developers. The company’s award-winning finger identification technology is currently used in some of the world’s largest identification deployments in order to improve security, guarantee identity and reduce identity theft. BIO-key’s software-based products are optimized to deliver fast and accurate user authentication on any device, network or internet environment, giving the company a highly scalable asset to promote future growth.

In March, the company expanded upon its existing product offerings through the announcement of EcoID, a compact USB touch fingerprint reader that delivers top quality identification at an unprecedented price point. With a manufacturer’s suggested retail price that’s substantially lower than other USB touch scanners, BIO-key will look to leverage this product in order to secure a larger share of the touch fingerprint reader market.

In May, BIO-key highlighted an additional, potentially expansive application for its technology when it announced a partnership with HealthCast, Inc. to deliver innovative solutions for single sign-on (SSO) and secure two-factor authentication for electronic prescription of controlled substances (EPCS) to clients across the United States. Potential customers include leading hospitals and hospital systems, such as Rady’s Children’s Hospital in San Diego, California, the first hospital in the country to deploy an EPCS solution utilizing the company’s proprietary EpicCare EMR technology.

“We understand that the doctors and nurses appreciate innovative technology that streamlines what was once a time-consuming and less secure process,” Jim Skidmore, vice president of sales at BIO-key, stated in a news release. “We are pleased to provide our solutions with those of HealthCast to meet these needs.”

Despite a decline in revenue during the first quarter of 2015, BIO-key is in a strong position to capitalize on the wide-spread potential applications of its technology in the months to come. By focusing its sales and marketing efforts on large enterprise and government opportunities, the company will look to achieve vastly increased revenue for the remaining quarters of 2015. In May, BIO-key reported a pipeline of sales opportunities valued at $30 million with which to promote this forecast financial growth.

“We made good progress across the business during the first quarter, helping to solidify our outlook for the balance of 2015 and beyond,” Michael DePasquale, chairman and chief executive officer of BIO-key, stated. “Though our first quarter sales performance fell below last year’s level… we are on target to achieve our full year revenue guidance of five to seven million dollars and expect to demonstrate the strength of our sales effort in our second quarter performance.”

For prospective investors, BIO-key’s recent progress toward expanding the market potential of its innovative biometric technology makes the company an intriguing option to consider moving forward. As it looks to convert upon the massive potential of its sales pipeline, look for BIO-key to take steps toward increasing its share of the domestic security software industry.

For more information, visit www.bio-key.com

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) is a clinical and commercial stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. The company’s leading product candidate, VAL-083, is a first-in-class small molecule chemotherapeutic that is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Previously, the drug candidate has been the subject of extensive research by the U.S. National Cancer Institute, and it is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China.

In June, DelMar presented an update on its phase I/II clinical trial of VAL-083, and the initial results provide a promising outlook for the company. Despite having failed prior treatment with standard front-line options and having a growing GBM tumor at the time of enrollment in the DelMar clinical trial, 59 percent of patients treated with VAL-083 recorded better than average survival rates. With proper dosing, an improved median overall survival of about nine months was achieved, which marked a meaningful survival benefit over currently available treatment options.

“The overall survival demonstrated at the higher doses in our clinical trial with only two cycles of treatment is clinically meaningful in comparison to published outcomes in this patient population,” Jeffrey Bacha, president and chief executive officer of DelMar, stated in a news release. “We consider these results to be positive and supportive of the further development of VAL-083 as a potential new therapy for GBM patients who have failed other available treatments.”

In the months to come, DelMar will initiate activities to prepare for advancement to registration-directed phase II/III clinical trials of VAL-083. As the company approaches the eventual commercialization of its drug candidate, early results indicate that it could have the potential to replace temozolomide as the standard of care in newly-diagnosed GBM patients whose tumors express features correlated with resistance to standard chemotherapy.

The potential market for DelMar’s drug candidate upon commercialization with the United States is expansive. According to the American Brain Tumor Association, nearly 700,000 people in the U.S. are currently living with a brain tumor, and nearly 70,000 new cases are diagnosed each year. Among these cases, approximately 17 percent are related to GBM. By providing an improved therapeutic option to temozolomide-resistant GBM, the company is in a strong position to promote sustainable growth moving forward.

For prospective shareholders, DelMar’s continued progress toward the domestic commercialization of VAL-083 makes the company an intriguing investment option in the coming months.

For more information, visit www.delmarpharma.com

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that provide unique and meaningful advantages to patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™, in the United States for the treatment of elevated serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Keryx’s novel treatment is also being commercialized in Japan as Riona® for the treatment of patients with all stages of CKD by the company’s Japanese partner.

According to the National Kidney Foundation, approximately 26 million Americans currently suffer from kidney disease. Among those individuals, approximately 450,000 people are on dialysis treatments. For these people, maintaining serum phosphorus levels is imperative. An additional report by the National Kidney Foundation states that prolonged exposure to elevated phosphorus levels has been shown to cause increases in calcium-phosphate production, which is commonly associated with increased morbidity and, in many cases, mortality. This data highlights the immense market potential of Auryxia moving forward.

In the first quarter of 2015, Keryx leveraged the marketability of its groundbreaking product to record promising financial results. The company reported total revenue of approximately $1.2 million, including both U.S. product revenue and license revenue associated with sales of Riona in Japan. These figures are expected to rise in the future. In June, Keryx announced that Auryxia had been added to the Medicare Part D formularies of two national insurance providers, giving the company access to approximately 65 percent of people in the United States currently taking phosphate binders.

“The inclusion of Auryxia on the major insurance providers’ Part D formularies, which we expect will start processing claims in the third quarter, significantly expands unrestricted access to Auryxia for people on dialysis and their caregivers,” Greg Madison, chief executive officer of Keryx, stated in a news release. “Looking ahead, we are focused on continuing to raise awareness of Auryxia’s clinical profile among the prescribing community and ensuring that the vast majority of dialysis patients have access to this important medicine.”

In addition to plans of adding a team of field sales representatives in the months to come, the company’s short-term objectives include expanding the indication for Auryxia to include the treatment of iron deficiency anemia in patients with CKD. In September 2014, Keryx initiated a phase III study for this indication which is expected to be completed by the end of 2015.

For more information, visit www.keryx.com